Brokerages expect that Jounce Therapeutics Inc (NASDAQ:JNCE) will report sales of $12.86 million for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Jounce Therapeutics’ earnings, with the lowest sales estimate coming in at $10.00 million and the highest estimate coming in at $14.90 million. Jounce Therapeutics posted sales of $12.99 million during the same quarter last year, which would indicate a negative year over year growth rate of 1%. The company is expected to issue its next quarterly earnings results on Thursday, March 14th.
On average, analysts expect that Jounce Therapeutics will report full-year sales of $57.17 million for the current fiscal year, with estimates ranging from $54.57 million to $60.00 million. For the next year, analysts forecast that the firm will post sales of $63.71 million, with estimates ranging from $43.00 million to $86.00 million. Zacks’ sales calculations are an average based on a survey of analysts that follow Jounce Therapeutics.
Jounce Therapeutics (NASDAQ:JNCE) last announced its quarterly earnings results on Tuesday, November 13th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.11. The firm had revenue of $14.53 million for the quarter, compared to analysts’ expectations of $12.80 million. Jounce Therapeutics had a negative net margin of 59.74% and a negative return on equity of 29.58%.
A number of brokerages have weighed in on JNCE. Zacks Investment Research cut shares of Jounce Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 17th. HC Wainwright set a $13.00 price target on shares of Jounce Therapeutics and gave the company a “buy” rating in a research report on Wednesday, November 14th. Cowen reaffirmed a “hold” rating on shares of Jounce Therapeutics in a research report on Tuesday, November 13th. Raymond James reduced their price target on shares of Jounce Therapeutics from $13.00 to $12.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 23rd. Finally, JPMorgan Chase & Co. reduced their price target on shares of Jounce Therapeutics from $12.00 to $10.00 and set a “hold” rating on the stock in a research report on Friday, August 10th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $11.92.
Hedge funds and other institutional investors have recently bought and sold shares of the company. NumerixS Investment Technologies Inc acquired a new position in shares of Jounce Therapeutics during the second quarter worth $132,000. Creative Planning acquired a new position in shares of Jounce Therapeutics during the third quarter worth $143,000. Bank of America Corp DE lifted its position in shares of Jounce Therapeutics by 243.4% during the second quarter. Bank of America Corp DE now owns 28,607 shares of the company’s stock worth $219,000 after purchasing an additional 20,276 shares in the last quarter. Trexquant Investment LP acquired a new position in shares of Jounce Therapeutics during the third quarter worth $216,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Jounce Therapeutics during the third quarter worth $231,000. 84.24% of the stock is currently owned by institutional investors and hedge funds.
Shares of JNCE stock opened at $4.32 on Monday. The company has a market cap of $141.26 million, a price-to-earnings ratio of -7.58 and a beta of 4.97. Jounce Therapeutics has a fifty-two week low of $3.30 and a fifty-two week high of $29.25.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.
Featured Article: Call Option
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.